Article
Low-dose rapamycin extends lifespan in a mouse model of mtDNA depletion syndrome.
Human molecular genetics - 1 Dec 2017
Siegmund Stephanie E, Yang Hua, Sharma Rohit, Javors Martin, Skinner Owen, Mootha Vamsi, Hirano Michio, Schon Eric A
Abstract excerpt
Mitochondrial disorders affecting oxidative phosphorylation (OxPhos) are caused by mutations in both the nuclear and mitochondrial genomes. One promising candidate for treatment is the drug rapamycin, which has been shown to extend lifespan in multiple animal models, and which was previously shown to ameliorate mitochondrial disease in a knock-out mouse model lacking a nuclear-encoded gene specifying an OxPhos...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.